Health
How CBD could help tackle opioid addiction
A new study will explore the effect of a unique CBD technology on reducing opioid consumption in chronic pain patients.
US biotech pharma company, ANANDA have announced a second clinical trial to evaluate the effect of cannabidiol in its unique delivery technology, on opioid sparing in participants with chronic pain syndromes.
An Investigational New Drug (IND) application has been approved by the US Food and Drug Administration (FDA) for the trial, which will be led by researchers at NYU Grossman School of Medicine, using ANANDA’s proprietary Liquid Structure™ CBD.
Pre-clinical and initial clinical studies show ANANDA’s Liquid Structure technology enhances the effectiveness and stability of CBD.
This innovation creates new potential to facilitate voluntary opioid sparing and the ability to reduce opioid intake in patients being treated for chronic pain.
“Approval of a second clinical trial with this world-renowned institution further advances applications for CBD in ANANDA’s patented delivery technology in an area that could positively impact the lives of a large number of people suffering from opioid addiction,” said Sohail R. Zaidi, ANANDA’s President.
“Opioids are a huge driver of overdose deaths in the US and non-addictive therapy is a significant unmet need.”
The trial is being conducted at NYU Grossman School of Medicine led by principal investigator Stephen Ross, MD, Associate Professor Department of Psychiatry and Director NYU Addictive Disorders and Experimental Therapeutics Research Laboratory.
Funding for this trial is from National Institute on Drug Abuse (NIDA), with additional support from ANANDA Scientific.
“Expanding research on therapeutic alternatives to opioid pharmacotherapies for chronic pain disorders, such as CBD medicinal products, is critical to reversing the opioid epidemic,” said Dr Ross.
“ANANDA’s commitment to safe, efficacious, high-quality products, paired with their groundbreaking delivery technology, creates tremendous opportunity for the development of evidence-based CBD medicinal products to reduce opioid intake and pain.
“We look forward to collaborating with ANANDA on this important clinical work.”
-
News6 months agoUK government accepts ACMD recommendations for CBD products
-
News6 months agoEurope’s first legal cannabis dispensaries to open under sixth Swiss pilot
-
News6 months agoUK government to permit electronic prescribing of cannabis medicines
-
Science5 months agoMedical cannabis doesn’t impair cognitive function – study
-
Industry5 months agoFirst Jersey-grown medicinal cannabis product to hit UK market
-
News6 months agoFive years of medical cannabis, five NHS prescriptions – how did we get here?
-
Medical cannabis6 months agoAlzheimer’s and medical cannabis: a new hope for patients?
-
News5 months agoJapan takes major step towards cannabis reform
